147 related articles for article (PubMed ID: 29531765)
1. The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure.
Binas D; Daniel H; Richter A; Ruppert V; Schlüter KD; Schieffer B; Pankuweit S
Open Heart; 2018; 5(1):e000750. PubMed ID: 29531765
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure.
Mueller T; Gegenhuber A; Leitner I; Poelz W; Haltmayer M; Dieplinger B
Clin Chim Acta; 2016 Dec; 463():158-164. PubMed ID: 27983996
[TBL] [Abstract][Full Text] [Related]
3. Soluble ST2, Galectin-3 and clinical prognosis of patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy: a correlation analysis.
Song B; Yao B; Dang H; Dong R
Cardiovasc Diagn Ther; 2020 Apr; 10(2):145-152. PubMed ID: 32420094
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 levels and long-term all-cause mortality and hospitalization in heart failure patients: a meta-analysis.
Cheng W; Maciej R; Thiele H; Büttner P
ESC Heart Fail; 2024 May; ():. PubMed ID: 38698741
[TBL] [Abstract][Full Text] [Related]
5. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
[TBL] [Abstract][Full Text] [Related]
6. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
[TBL] [Abstract][Full Text] [Related]
7. ST2 as a novel prognostic marker in end-stage renal disease patients on hemodiafiltration.
Homsak E; Ekart R
Clin Chim Acta; 2018 Feb; 477():105-112. PubMed ID: 29221927
[TBL] [Abstract][Full Text] [Related]
8. Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients.
Wojciechowska C; Romuk E; Nowalany-Kozielska E; Jacheć W
Hellenic J Cardiol; 2017; 58(5):350-359. PubMed ID: 28363768
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
[TBL] [Abstract][Full Text] [Related]
10. Long-Term and Short-Term Prognostic Value of Circulating Soluble Suppression of Tumorigenicity-2 Concentration in Chronic Heart Failure: A Systematic Review and Meta-Analysis.
Dong G; Chen H; Zhang H; Gu Y
Cardiology; 2021; 146(4):433-440. PubMed ID: 33902050
[TBL] [Abstract][Full Text] [Related]
11. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study.
Dieplinger B; Egger M; Haltmayer M; Kleber ME; Scharnagl H; Silbernagel G; de Boer RA; Maerz W; Mueller T
Clin Chem; 2014 Mar; 60(3):530-40. PubMed ID: 24401186
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Protasov VN; Narusov OY; Skvortsov AA; Protasova DE; Kuznetsova TV; Petrukhina AA; Masenko VP; Tereshchenko SN
Kardiologiia; 2019 Jan; 59(1S):53-64. PubMed ID: 30706839
[TBL] [Abstract][Full Text] [Related]
13. Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy.
You H; Jiang W; Jiao M; Wang X; Jia L; You S; Li Y; Wen H; Jiang H; Yuan H; Huang J; Qiao B; Yang Y; Jin M; Wang Y; Du J
Can J Cardiol; 2019 Jun; 35(6):727-735. PubMed ID: 31151708
[TBL] [Abstract][Full Text] [Related]
14. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
[TBL] [Abstract][Full Text] [Related]
15. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology.
Broch K; Ueland T; Nymo SH; Kjekshus J; Hulthe J; Muntendam P; McMurray JJ; Wikstrand J; Cleland JG; Aukrust P; Gullestad L
Eur J Heart Fail; 2012 Mar; 14(3):268-77. PubMed ID: 22302661
[TBL] [Abstract][Full Text] [Related]
16. Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.
Hu DJ; Xu J; Du W; Zhang JX; Zhong M; Zhou YN
Int J Cardiovasc Imaging; 2016 Dec; 32(12):1725-1733. PubMed ID: 27566192
[TBL] [Abstract][Full Text] [Related]
17. Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction.
Cui Y; Qi X; Huang A; Li J; Hou W; Liu K
Med Sci Monit; 2018 Jul; 24():5139-5146. PubMed ID: 30039808
[TBL] [Abstract][Full Text] [Related]
18. ST2 elevation in heart failure, predictive of a high early mortality.
Dalal JJ; Digrajkar A; Das B; Bansal M; Toomu A; Maisel AS
Indian Heart J; 2018; 70(6):822-827. PubMed ID: 30580851
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure.
Tang WH; Wu Y; Grodin JL; Hsu AP; Hernandez AF; Butler J; Metra M; Voors AA; Felker GM; Troughton RW; Mills RM; McMurray JJ; Armstrong PW; O'Connor CM; Starling RC
JACC Heart Fail; 2016 Jan; 4(1):68-77. PubMed ID: 26656144
[TBL] [Abstract][Full Text] [Related]
20. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy.
Rossi A; Dini FL; Faggiano P; Agricola E; Cicoira M; Frattini S; Simioniuc A; Gullace M; Ghio S; Enriquez-Sarano M; Temporelli PL
Heart; 2011 Oct; 97(20):1675-80. PubMed ID: 21807656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
